Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.

Competing Interests: E.F., C.M., J.S., A.Z., B.W., J.v.W., and M.A.-K. are employees of ViiV Healthcare and own stock in GSK. N.E. has received grants from Merck; honoraria for participation in presentations or educational events from Merck, Gilead, Janssen, and GSK; and travel support from Gilead, Janssen, and GSK; and has participated in data safety monitoring or advisory boards for Merck, Gilead, and GSK. RGulminetti has received grants from Gilead and ViiV Healthcare, which were paid to his institution; received consulting fees from AbbVie, Gilead, ViiV Healthcare, and Merck Sharp & Dohme; received honoraria from Gilead, ViiV Healthcare, and Merck Sharp & Dohme; provided expert testimony for Gilead and ViiV Healthcare; and received travel support from Gilead. D.H. has served as a principal investigator through her institution, received honoraria for participation in speakers bureaus, and received travel support from GSK/ViiV Healthcare; has participated in advisory boards for ViiV Healthcare; and serves on the Georgia ADAP committee. RGrove is an employee of and owns stock in GSK. J.S.M. and H.-C.T. have no conflicts of interest to disclose.